Sugi Predict

Sugi Predict / Compounds / Glutamine

Glutamine

Glutamine

SCHEMBL17713530

CC(C)C[C@H](N)C(=O)O.CC[C@H](C)[C@H](N)C(=O)O.NC(=O)CC[C@H](N)C(=O)O.NC(=O)C[C@H](N)C(=O)O.NCC(N)=O.N[C@@H](CS)C(=O)O.O=C(O)[C@@H]1CCCN1

nearest known ligand 0.32

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC5A2

The experimentally established mechanism targets of Glutamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ ALOX15 P16050 1/20 0.32
▸ BLM P54132 1/20 0.32
▸ PMP22 Q01453 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ REN P00797 1/20 0.31
▸ SLC7A5 Q01650 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tyrosine SCHEMBL20855327 0.91 REN (0.35) RENSLC7A5
Tyrosine SCHEMBL5151728 0.89 REN (0.36) RENSLC7A5
Leucine SCHEMBL4395800 0.88 SLC7A5 (0.36) RENSLC7A5
Glutamine SCHEMBL8392144 0.86 ALOX15 (0.43) ALOX15BLMPMP22KMT2A
Glutamine SCHEMBL27834300 0.86 ALOX15 (0.43) ALOX15BLMPMP22KMT2A
Glutamine SCHEMBL10428552 0.84 ALOX15 (0.34) ALOX15BLMPMP22KMT2A
Glutamine SCHEMBL6255119 0.84 ALOX15 (0.38) ALOX15BLMPMP22KMT2ASLC7A5
D-Glutamate SCHEMBL28976126 0.84 GRM8 (0.38) —
Isoleucine SCHEMBL25386165 0.84 NOS2 (0.35) REN
Isoleucine SCHEMBL10428546 0.84 NOS2 (0.35) REN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3212212-A1 POWDER FORMULATION GlaxoSmithKline Intellectual Property Development Limited (GB) 2017-09-06 — — EP disclosed
WO-2016067252-A1 POWDER FORMULATION GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2016-05-06 — — WO disclosed